New hope for heart inflammation sufferers: drug switch study launches
NCT ID NCT07288216
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 27 times
Summary
This study tests a new drug, KPL-387, for people with recurrent pericarditis (repeated heart lining inflammation) that is currently well-controlled with standard treatments. About 80 adults will switch from their usual therapy to KPL-387 alone to see if it prevents flare-ups and improves quality of life. The goal is to find a safer, effective long-term option for managing this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site 001
RECRUITINGNorfolk, Virginia, 23507, United States
-
Investigational Site 002
RECRUITINGSanta Monica, California, 90404, United States
-
Investigational Site 003
RECRUITINGNew York, New York, 10032, United States
-
Investigational Site 004
RECRUITINGCharlottesville, Virginia, 22903, United States
-
Investigational Site 005
RECRUITINGAustin, Texas, 78705, United States
-
Investigational Site 006
RECRUITINGHouston, Texas, 77030, United States
-
Investigational Site 007
RECRUITINGLondon, SE1 7EH, United Kingdom
-
Investigational Site 008
RECRUITINGRichmond, Virginia, 23284, United States
-
Investigational Site 009
RECRUITINGCincinnati, Ohio, 45219, United States
-
Investigational Site 010
RECRUITINGOttawa, Ontario, K1N 6N5, Canada
-
Investigational Site 011
RECRUITINGNew York, New York, 10016, United States
-
Investigational Site 012
RECRUITINGLondon, EC1A 7BE, United Kingdom
-
Investigational Site 013
RECRUITINGChicago, Illinois, 60611, United States
-
Investigational Site 014
RECRUITINGLos Angeles, California, 90048, United States
-
Investigational Site 015
RECRUITINGBarcelona, 08035, Spain
-
Investigational Site 016
RECRUITINGMadrid, 28850, Spain
-
Investigational Site 017
RECRUITINGMadrid, 28034, Spain
-
Investigational Site 018
RECRUITINGValencia, 46015, Spain
-
Investigational Site 019
RECRUITINGBarcelona, 08017, Spain
-
Investigational Site 020
RECRUITINGWarsaw, 02-507, Poland
-
Investigational Site 021
RECRUITINGMilan, 20157, Italy
-
Investigational Site 022
RECRUITINGLondon, NW3 2QG, United Kingdom
-
Investigational Site 023
RECRUITINGNea Ionia, 142 33, Greece
Conditions
Explore the condition pages connected to this study.